Business
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025
CAMBRIDGE, Mass., March 27, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today provided a corporate update following the filing of its 10-K on Friday, March 27, 2026, which reported financial results for the fourth quarter and year ended December 31, 2025.
About this update from Enveric Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/efde4bbd095bfbe30526815747c4e91e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/k.IUNvriU_kxDEevN_6yBw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/efde4bbd095bfbe30526815747c4e91e","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/RVJJXBTNQl2dIK3EulPlgw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/efde4bbd095bfbe30526815747c4e91e","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Product Development Highlights:","length":31,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements in animal models of severe chronic depression and despair and in post-traumatic stress disorder (PTSD)","length":219,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Identified neuroplastogen candidates with potential to promote brain-derived neurotrophic factor (BDNF) signaling, an established therapeutic target for neurodegenerative disease","length":178,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":397,"olType":false},{"type":"text","content":"Corporate and Business Development Highlights:","length":46,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced the withdrawal of the Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals against Enveric’s issued U.S. Patent No. 12,138,276, which appears relevant to the bretisilocin (GM-2505) molecule acquired by AbbVie, Inc.","length":239,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Continued to strengthen Enveric’s expansive IP portfolio directed to molecules intended to provide non-hallucinogenic treatment options. Multiple patents and notices of allowance were issued for its EVM301 Series, including a novel family of molecules including melatonin receptor-targeting compounds, and for its EVM401 Series","length":327,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":566,"olType":false},{"type":"text","content":"CA...